Manier, S., Puig, N., Leleu, X., Oriol, A., Hulin, C., García-Sanz, R., Corre, J., San-Miguel, J., Facon, T., Lee, H., Forsberg, P., Chatterjee, K., Svensson, A., Talati, C., He, S., Doerr, T., Arriola, E., Dillon, M., Lin, J., Nguyen, L., Wang, F., Mateos, M. (2025). A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. https://doi.org/10.1182/blood-2025-2288